Gilead Sciences, Inc.
GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment ofā¦ read more
Healthcare
Drug ManufacturersāGeneral
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$133.05
Price-1.40%
-$1.89
1Y
Price
Market Cap
$165.191b
Large
Price/Earnings 3y Avg5y Avg
15.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+33.8%
EBITDA Margin+29.0%
Net Profit Margin+34.9%
Free Cash Flow Margin+33.8%
EBITDA Margin+29.0%
Net Profit Margin+34.9%
Free Cash Flow MarginRevenue
$29.734b
+1.0%
1y CAGR+3.1%
3y CAGR+2.2%
5y CAGREarnings
$9.216b
+8.3%
1y CAGR+529.9%
3y CAGR+403.3%
5y CAGREPS
$7.34
+8.3%
1y CAGR+533.6%
3y CAGR+406.1%
5y CAGRBook Value
$23.431b
$56.278b
Assets$32.847b
Liabilities$22.174b
DebtDebt to Assets
39.4%
1.7x
Debt to EBITDAFree Cash Flow
$10.229b
+8.2%
1y CAGR+12.9%
3y CAGR+6.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company